Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone for No-Reflow in STEMI
NCT06552442Phase 2Completed
- Sponsor
- Amosov National Institute of Cardiovascular Surgery
- Start
- Sep 2020
- Primary completion
- Jan 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of methylprednisolone in no-reflow phenomenon, sponsored by Amosov National Institute of Cardiovascular Surgery. Primary endpoint: Restoration of coronary blood flow at 3 minutes. Started Sep 2020; status: completed.
02
Drugs
methylprednisolone
03
Conditions
no-reflow phenomenon
Beyond the preview
Go deeper on NCT06552442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06552442.